Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
AssigneeGlycovaxyn AG
InventorsFabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
Claims13
A method of producing a composition comprising a bioconjugate in a bioreactor, wherein said bioconjugate comprises a protein linked to an O antigen, comprising the steps:
- (i) expressing in bacteria:
- modified EPA protein containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline, or the AcrA protein;
- an oligosaccharyl transferase;
- and one or more O antigens;
- (ii) growing the bacteria for a period of time to produce an amount of the bioconjugate comprising the AcrA protein or the modified EPA protein linked to the one more O antigens;
- (iii) extracting periplasmic proteins;
- and
- (iv) separating the bioconjugate from the extracted periplasmic proteins by anionic exchange.
Dependencies are inferred from the claim text.